Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Solal-Celigny, P. Imrie, K Belch, A Robinson, KS Cunningham, D. Marcus, R et al.[show all]

Document type	Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection
Publication date	2005
Language	Anglais
Conference	"47th Annual Meeting of the American-Society-of-Hematology", Atlanta(Ga) (Dec 10-13, 2005)
Journal information	"Blood" - Vol. 106, no. 11, p. 106A (2005)
Peer reviewed	yes
issn	0006-4971
e-issn	1528-0020
Publisher	Amer Soc Hematology (Washington)
Affiliation	UCL - Autre
Links	http://hdl.handle.net/2078.1/60100[Handle]

Bibliographic reference	Solal-Celigny, P. ; Imrie, K ; Belch, A ; Robinson, KS ; Cunningham, D. ; et. al. Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up..47th Annual Meeting of the American-Society-of-Hematology (Atlanta(Ga), Dec 10-13, 2005). In: Blood, Vol. 106, no. 11, p. 106A (2005)
Permanent URL	http://hdl.handle.net/2078.1/60100